Kidney injury molecule-1 (KIM-1) is overexpressed in renal cell carcinoma (RCC), and consistent shedding of this cell-surface protein into the circulation makes it a promising blood-based biomarker for this disease. Herein, we outline potential roles of circulating KIM-1 in diagnosis, prognostication and therapeutic monitoring of RCC, as well as research priorities for clinical translation of this biomarker.
Bonventre, J. V.
Kidney injury molecule-1: a translational journey. Trans.
Am. Clin.
Climatol. Assoc.
125 , 293–299 (2014). Cuadros, T.
et al. HAVCR/KIM-1 activates the IL-6/STAT-3 pathway in clear cell renal cell carcinoma and determines tumor progression and patient outcome.
Cancer Res 74 , 1416–1428 (2014). Brooks, C.
R. et al.
KIM ‐1‐/ TIM ‐1‐mediated phagocytosis links ATG 5‐/ ULK 1‐dependent clearance of apoptotic cells to antigen presentation. EMBO J 34 , 2441–2464 (2015).
Scelo, G. et al.
KIM-1 as a blood-based marker for early detection of kidney cancer: a prospective nested case-control study. Clin.
Cancer Res. 24 , 5594–5601 (2018).
Xu, W. et al.
Nature Reviews Clinical Oncology published a clinical update in Oncology on 20 May 2026.
The item focuses on Current evidence and future directions for KIM-1 as a blood-based biomarker in RCC.
Review the original article for the full source wording and details.